EP Patent

EP2335686A1 — An aqueous intravenous nanosuspension with reduced adverse effects

Assigned to Lek Pharmaceuticals dd · Expires 2011-06-22 · 15y expired

What this patent protects

The present invention relates to an aqueous nanosuspension formulation comprising a drug possessing low intrinsic water solubility, e.g. amiodarone. It also provides a method for the preparation of intravenous formulation comprising amiodarone, with markedly decreased adverse eff…

USPTO Abstract

The present invention relates to an aqueous nanosuspension formulation comprising a drug possessing low intrinsic water solubility, e.g. amiodarone. It also provides a method for the preparation of intravenous formulation comprising amiodarone, with markedly decreased adverse effects.

Drugs covered by this patent

Patent Metadata

Patent number
EP2335686A1
Jurisdiction
EP
Classification
—
Expires
2011-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Lek Pharmaceuticals dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.